Press "Enter" to skip to content

New patent expiration for Nabriva drug XENLETA

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Nabriva drug XENLETA

Annual Drug Patent Expirations for XENLETA
Annual Drug Patent Expirations for XENLETA

Xenleta is a drug marketed by Nabriva and is included in two NDAs. There are four patents protecting this drug.

Drug patent litigation for XENLETA.

This drug has one hundred and four patent family members in forty-one countries.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Nabriva drug XENLETA
    Get the DrugPatentWatch Daily Briefing

    ✓ Patent Expirations and Generic Entry

    ✓ Insightful Articles & Case Studies

    ✓ Patent Litigation & Challenges

    ✓ 505(b)(2) & Biosimilars

    ✓ Industry Trends

    DrugPatentWatch - Make Better Decisions